Explore Fosun Pharma

  • Hot News

    Fosun Pharma Releases 2018 Annual Results:Adhere to Innovation and Internationalization with Steady Growth in Pharmaceutical Manufacturing and R&D segment Revenue RMB 24.92 billion, up 34.45% YOY Cash flows from operating activities RMB 2.95 billion, up 14.34% YOY R&D Investment RMB 2.51 billion, up 63.92% YOY

    On 25 March 2019, Shanghai Fosun Pharmaceutical (Group) Co., Ltd (Fosun Pharma, stock code:600196.SH,02196.HK), a leadin...

    Details
  • Hot News

    Fosun Pharma Has Opened a New Era for Biosimilar in China Henlius Receives NMPA Approval for Its First Product HLX01

    Recently, HLX01 (rituximab injection), independently developed by Shanghai Henlius Biotech, Inc.(Henlius), Fosun Pharma’...

    Details
  • Hot News

    Conference Announcement | FOR A MALARIA-FREE WORLD Fosun Pharma at the 7th MIM Pan African Malaria Conference

    The 7th Multilateral Initiative on Malaria (MIM) Pan-African Malaria Conference (Hereinafter referred to as MIM) will...

    Details
  • Hot News

    Strengthening Innovation and R&D, Deepening Internationalization Strategy

    Fosun Pharma Recorded Revenue of RMB18,534 1million in 2017, up by 26.69% YoY Net profit attributable to shareholders of the listed company after deduction of non-recurring profit or loss Recorded RMB2,346 million, up by 12.10% YoY R&D Investment amounted to RMB1,529 million, up by 38.26% YoY

    Details

Operation Excellence

Continued to Promote

FOPEX

Fosun Pharma
Operation Excellence

Innovation

Fosun Pharma Shares (A+H)

SH 600196

24.79

+0.52 +2.80%

2015-04-15 14:48:05

HK 02196

25.85

+0.52 +12.10%

2015-04-15 14:48:05

Refer to the Annual Financial Report

Recruitment

0
Recruitment Posts

Join Fosun Pharma